江中藥業(600750.SH):擬參與設立華潤醫藥產業投資基金二期
格隆匯7月17日丨江中藥業(600750.SH)公佈,為落實公司發展戰略,提高優質資源獲取與配置能力,儲備與公司戰略方向相匹配的項目資源,同時獲得一定的投資收益,公司於2025年7月16日召開第十屆董事會第六次會議,以3票同意、0票反對、6票迴避的表決結果審議通過了《關於參與設立華潤醫藥產業投資基金二期暨關聯交易的議案》,同意公司與普通合夥人華潤醫藥(成都)企業管理合夥企業(有限合夥)(暫定名,以工商核准名為準)及華潤醫藥投資有限公司、華潤博雅生物製藥集團股份有限公司、東阿阿膠股份有限公司、華潤雙鶴藥業股份有限公司、成都潤藥產業投資合夥企業(有限合夥)(暫定名,以工商核准名為準)等10家有限合夥人共同設立華潤醫藥(成都)創新投資基金合夥企業(有限合夥)(暫定名,以工商核准名為準,簡稱“本基金”或“該基金”)。該基金規模為10億元人民幣,深圳市華潤資本股權投資有限公司為該基金管理人。公司作為有限合夥人,以自有資金認繳出資總額4,000萬元人民幣,持有該基金4%的財產份額,以其認繳出資額為限承擔有限責任。本次合夥協議尚未完成簽署,協議內容和具體操作方式以各方最終簽署的正式協議為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.